title: No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer.
abstract: The amplification and overexpression of the human epidermal growth factor receptor 2 gene HER-2 (also known as c-erb-B2 or neu) have been shown to be associated with bladder cancer and its progression. Recent studies indicated an association between the Ile to Val polymorphism at codon 655 of HER-2 and susceptibility to breast cancer. To investigate the correlation between the Ile/Val polymorphism and the susceptibility and progression of bladder cancer, we analyzed the polymorphism in 232 patients with transitional cell carcinoma of the bladder and 408 normal controls. The frequencies of the Ile/Ile, Ile/Val and Val/Val genotype were 75.9%, 21.6% and 2.6%, respectively, in patients with bladder cancer and 75.7%, 23.0% and 1.2%, respectively, in controls. Statistical analyses of the genotype prevalence showed no significant difference between bladder cancer patients and normal controls (p = 0.419). Moreover, no significant differences in the genotype prevalence were observed when the patients were stratified according to the tumor grade, stage and smoking habits. When the Ile/Ile genotype was compared to the Ile/Val and Val/Val genotypes, a significant difference was found only between the patients with tumor stage Ta and those with T1-4 (age, gender and smoking habits-adjusted odds ratio = 2.13, 95% confidence interval = 1.09-4.15, p = 0.027). When the Ile/Ile + Ile/Val genotypes compared to the Val/Val genotype, no significant findings were observed. These results suggested that the HER-2 polymorphism at codon 655 is unlikely to be associated with the onset of bladder cancer. Furthermore, the findings suggest no association between this polymorphism and the disease progression in bladder cancer, although the possibility remains that the Ile/Ile genotype may be related to an increased risk of disease progression.
authors.affiliation: Department of Urology, Akita University School of Medicine, Akita, Japan.
authors.forename: Lizhong
authors.initials: L
authors.lastname: Wang
authors.forename: Tomonori
authors.initials: T
authors.lastname: Habuchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kamoto
authors.forename: Tao
authors.initials: T
authors.lastname: Zuo
authors.forename: Kenji
authors.initials: K
authors.lastname: Mitsumori
authors.forename: Norihiko
authors.initials: N
authors.lastname: Tsuchiya
authors.forename: Kazunari
authors.initials: K
authors.lastname: Sato
authors.forename: Osamu
authors.initials: O
authors.lastname: Ogawa
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kato
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D003062:Codon; D017931:DNA Primers / Q000737:chemistry; D005260:Female; D018734:Genes, erbB-2; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012307:Risk Factors; D017422:Sequence Analysis, DNA; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000235:genetics*
chemical_list: D003062:Codon; D017931:DNA Primers; D018719:Erb-b2 Receptor Tyrosine Kinases